Paradigm Biopharma: Phase 3 OA Trial Continues Unchanged Following Formal DSMB 80% Safety Review, September Interim Analysis on Track
Amplia Therpeutics: SCIENTIFIC PAPER DETAILING PRECLINICAL STUDIES OF NARMAFOTINIB IN PANCREATIC CANCER NOW ONLINE
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
PYC Therapeutics: POLYCYSTIC KIDNEY DISEASE – SAFETY COMMITTEE APPROVES DOSE ESCALATION IN PHASE 1B STUDY
Paradigm receives $5.75 million boost to cash reserves through Australian Government’s R&D Tax Incentive
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
Monash and partners to build new lab to fast-track drug invention, trials and commercialisation – Monash University
Neurizon: HEALEY ALS Platform Trial Regimen I enrolment completed – Topline results for NUZ-001 accelerated to Q2 CY2027
Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics